Antibe Therapeutics, a Canadian pharma company has completed enrollment of patients in a phase 2B dose-ranging, efficacy clinical trial of its lead drug candidate ATB-346 for its use in reducing osteoarthritis (OA) pain.
The mid-stage clinical study will assess the effectiveness of ATB-346 in the reduction of OA knee pain in comparison to placebo in 360 patients.
According to Antibe Therapeutics, the final patients will be subject to treatment for a couple of weeks, followed by a monitoring period of two weeks and analysis of the primary endpoint data.
The primary endpoint in the phase 2B is the variation in OA knee pain of ATB-346 compared to placebo as measured by the WOMAC subscale pain score, which is considered to be the gold standard in pain assessment for arthritis trials.
Patients have been randomly grouped to receive placebo or one 150 mg, 200 mg or 250 mg of ATB-346 given daily.
Antibe Therapeutics expects to release top-line results of the ATB-346 clinical trial within six weeks.
ATB-346, which releases hydrogen sulfide, is derived from naproxen.